Hikma Builds Presence in US Injectables Market via Boehringer Ingelheim Asset Purchase
By Heather Cartwright
Pharma Deals Review: Vol 2014 Issue 6 (Table of Contents)
Published: 18 Jun-2014
DOI: 10.3833/pdr.v2014.i6.2043 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Hikma Pharmaceuticals has agreed to acquire the assets of Bedford Laboratories, the US generic injectables business of Boehringer Ingelheim’s Ben Venue Laboratories, in a deal worth up to US$300 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS